Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Coronary Artery Disease
100%
Intravascular Ultrasound
68%
Ischemia
48%
ST Segment Elevation Myocardial Infarction
44%
Percutaneous Coronary Intervention
44%
Atherosclerotic Plaque
44%
Lipid
40%
Coronary Artery
35%
Risk Stratification
34%
Myocardial Infarction
29%
Cardiovascular Risk
28%
Endotype
27%
Angina pectoris
24%
Intravascular Imaging
22%
Biological Marker
22%
Single-Photon Emission Computed Tomography
22%
Revascularization
22%
Treatment Planning
22%
Intercellular Adhesion Molecule 1
22%
Carotid Artery Stenting
22%
Atrial Fibrillation
22%
Exome Sequencing
22%
Drug-Eluting Stent
22%
Acute Coronary Syndrome
22%
Hypertriglyceridemia
22%
Carotid Artery
22%
Triacylglycerol
22%
Disease Management
22%
Polygenic Risk Score
22%
Patient Population
22%
near Infrared Spectroscopy
18%
Coronary Angiography
18%
Plasminogen Activator Inhibitor-1
14%
Atherosclerosis
14%
Vulnerable Plaque
11%
N Ethyl 2 [N (6 Methoxy 3 Pyridinyl) 2 Methylbenzenesulfonamido] N (3 Pyridinylmethyl)acetamide
11%
Heart Muscle Perfusion
9%
Dyslipidemia
9%
Low Density Lipoprotein Cholesterol
8%
Apoplexy
7%
Artery Lesion
7%
Infarction
7%
Prevalence
7%
Protective Factor
7%
Proportional Hazards Model
7%
Regression Analysis
7%
Long-Term Outcome
7%
All Cause Mortality
7%
Thrombosis
7%
Cardiac Magnetic Resonance Imaging
7%
Pharmacology, Toxicology and Pharmaceutical Science
Cardiovascular Risk
71%
Lipid
69%
Low Density Lipoprotein Cholesterol
43%
Inclisiran
43%
Statin (Protein)
36%
Hypertension
33%
Ezetimibe
32%
Coronary Artery Disease
30%
Rosuvastatin
28%
Atorvastatin
28%
Biological Marker
25%
Atherosclerotic Plaque
24%
ST Segment Elevation Myocardial Infarction
22%
Antihypertensive Agent
22%
Antihypertensive Therapy
22%
Amlodipine
22%
Intercellular Adhesion Molecule 1
22%
Empagliflozin
22%
microRNA 155
22%
Circulating microRNA
22%
Kexin
22%
Subtilisin
22%
Carbon Dioxide
22%
Hippophae rhamnoides
22%
microRNA 126
18%
Alirocumab
16%
Infrared Spectroscopy
15%
Heart Infarction
14%
Fluspirilene
14%
Plasminogen Activator Inhibitor 1
14%
Prospective Study
14%
N Ethyl 2 [N (6 Methoxy 3 Pyridinyl) 2 Methylbenzenesulfonamido] N (3 Pyridinylmethyl)acetamide
11%
Prevalence
11%
Maturity Onset Diabetes of the Young
11%
microRNA
9%
Hypolipemia
9%
Infarction
7%
Triacylglycerol
6%
C Peptide
6%
Oleic Acid
6%
Combination Therapy
5%
Dipeptidyl Peptidase IV Inhibitor
5%
Congestive Heart Failure
5%
Retrospective Study
5%
Adverse Event
5%
Atherosclerosis
5%
Nursing and Health Professions
Atherosclerotic Plaque
44%
Lipid
25%
Patient Compliance
22%
Antihypertensive Agent
22%
Inclisiran
22%
Systolic Blood Pressure
22%
Low Density Lipoprotein Cholesterol
22%
Fluspirilene
22%
Neointima
22%
microRNA 126
22%
microRNA 155
22%
microRNA 145
22%
Blood Pressure
16%
Adherence
16%
Medication Compliance
16%
Hypolipemia
7%
near Infrared Spectroscopy
7%
Intravascular Ultrasound
6%
University Hospital
5%
Prevalence
5%
Arterial Pressure
5%
Blood Pressure Monitor
5%
Age Groups
5%
Hypertension
5%
